Table 2 The classes and specific chemotherapeutic agents used by cancer patients, Uganda

Plant alkaloids and other natural products (143, 47.7%)

Vincristine (57, 19%), Docetaxel (44, 14.7%), Paclitaxel (29, 9.7%), Etoposide (13, 4.3%), Irinotecan (2, 0.7%), Vinblastine (2, 0.7%)

Antimetabolites (103, 34.3%)

Capecitabine (32, 10.7%), Fluorouracil (30, 10%), Methotrexate (30, 10%), Gemcitabine (14, 4.7%), Mercaptopurine (10, 3.3%), Cytarabine (10, 3.3%)

Platinum analogues (66, 22%)

Oxaliplatin (32, 10.7%), Cisplatin (25, 8.3%), Carboplatin (9, 3%)

Cytotoxic antimetabolites (62, 20.7%)

Doxorubicin (44, 14.7%), Bleomycin (10, 3.3%), Epirubicin (7, 2.3%), Dactinomycin (7, 2.3%), Daunorubicin (5, 1.7%)

Alkylating agents (58, 19.3%)

Cyclophosphamide (41, 13.7%), Dacarbazine (9, 3%), Ifosfamide (3, 1%), Melphalan (3, 1%), Chlorambucil (2, 0.7%)

Endocrine therapy (53, 17.7%)

Goserelin (35, 11.7%), Bicalutamide (27, 9%), Tamoxifen (6, 2%), Abiraterone (4, 1.3%), Anastrozole (2, 0.7%)

Protein kinase inhibitors (23, 7.7%)

Imatinib (15, 5%), Erlotinib (6, 2%), Nintedanib (2, 0.7%), Sorafenib (1, 0.3%), Bortezomib (1, 0.3%)

Miscellaneous (14, 4.7%)

Thalidomide (6, 2%), Asparaginase (5, 1.7%), Arsenic-trioxide (2, 0.7%), Rituximab (1, 0.3%), Tamsulosin (1, 0.3%)